Sustained deep molecular responses in patients switched to nilotinib due to persistent BCR-ABL1 on imatinib: final ENESTcmr randomized trial results

[1]  T. Hughes,et al.  Moving treatment-free remission into mainstream clinical practice in CML. , 2016, Blood.

[2]  I. Flinn,et al.  Long-term benefits and risks of frontline nilotinib vs imatinib for chronic myeloid leukemia in chronic phase: 5-year update of the randomized ENESTnd trial , 2016, Leukemia.

[3]  K. Spiekermann,et al.  Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV , 2015, Leukemia.

[4]  B. Leber,et al.  Deep molecular responses achieved in patients with CML-CP who are switched to nilotinib after long-term imatinib. , 2014, Blood.

[5]  Francisco Cervantes,et al.  European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. , 2013, Blood.

[6]  D. Rakheja,et al.  IDH mutations in acute myeloid leukemia. , 2012, Human pathology.

[7]  R. Hills,et al.  The prognostic significance of IDH2 mutations in AML depends on the location of the mutation. , 2011, Blood.

[8]  A. Nagler,et al.  Multicenter independent assessment of outcomes in chronic myeloid leukemia patients treated with imatinib. , 2011, Journal of the National Cancer Institute.

[9]  H. Dombret,et al.  Prognostic impact of isocitrate dehydrogenase enzyme isoforms 1 and 2 mutations in acute myeloid leukemia: a study by the Acute Leukemia French Association group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  Ricardo Pasquini,et al.  Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. , 2010, The New England journal of medicine.

[11]  Jaspal Kaeda,et al.  Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Z. Rudzki,et al.  BCR-ABL Messenger RNA Levels Continue to Decline in Patients with Chronic Phase Chronic Myeloid Leukemia Treated with Imatinib for More Than 5 Years and Approximately Half of All First-Line Treated Patients Have Stable Undetectable BCR-ABL Using Strict Sensitivity Criteria , 2007, Clinical Cancer Research.

[13]  Francisco Cervantes,et al.  Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. , 2006, The New England journal of medicine.

[14]  Susan O'Brien,et al.  Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. , 2006, Blood.

[15]  Rajyalakshmi Luthra,et al.  Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. , 2011, American journal of clinical pathology.